Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
286
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

Prajwal BodduDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0001-9408-5882View further author information
ORCID Icon,
Preetesh JainDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Gautam BorthakurDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Srdan VerstovsekDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Naval DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Tapan KadiaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Elias JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jorge CortesDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-8636-1071View further author information
ORCID Icon &
Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
 show all
Pages 3172-3180 | Received 02 Feb 2019, Accepted 04 May 2019, Published online: 24 May 2019

References

  • Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028–1035.
  • Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–2088.
  • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
  • Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.
  • Jain P, Kantarjian H, Jabbour E, et al. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015;2:e376–383.
  • Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612–621.
  • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.
  • Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424–430.
  • Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009;113:4497–4504.
  • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–2270.
  • Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197–2203.
  • Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392–397.
  • Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–237.
  • Baccarani M, Castagnetti F, Gugliotta G, et al. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94:141–147. Suppl
  • (CTEP) NCICTEP. Common Toxicity Criteria for Adverse Events v4.03 (CTCAE) 2009.
  • Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;109:1556–1560.
  • Eghtedar A, Kantarjian H, Jabbour E, et al. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:477–484.
  • Boddu P, Shah AR, Borthakur G, et al. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018;59:1312–1322.
  • Rivera VM, Pritchard JR, Gonzalvez F, et al. Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events. Blood. 2014;124:1783–1783.
  • Albrecht-Schgoer K, Huber K, Grebien F, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood. 2013;122:257–257.
  • Talbert DR, Doherty KR, Trusk PB, et al. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015;143:147–155.
  • Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.
  • Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900–908.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.